Oral anticoagulants and the risk of osteoporotic fractures among elderly

Pharmacoepidemiology and Drug Safety

Volumn 13, Issue 5, 2004, Pages 289-294

  Pilon, Danielle ^a   Castilloux, Anne Marie ^a   Dorais, Marc ^a   LeLorier, Jacques ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Database study; Oral anticoagulants; Osteoporosis; Osteoporotic fracture; Pharmacoepidemiology

Indexed keywords

ANTICOAGULANT AGENT; BENZODIAZEPINE DERIVATIVE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CORTICOSTEROID; ESTROGEN; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEVODOPA; LEVOTHYROXINE; SEROTONIN UPTAKE INHIBITOR; THIAZIDE DIURETIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

AGED; ARTICLE; BONE DENSITY; CANADA; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; FRAGILITY FRACTURE; HEALTH INSURANCE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OSTEOPOROSIS; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; CASE-CONTROL STUDIES; DATABASES, FACTUAL; FEMALE; HIP FRACTURES; HUMANS; MALE; OSTEOPOROSIS; PHARMACOEPIDEMIOLOGY; QUEBEC; RISK FACTORS;

EID: 2542510728     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.888     Document Type: Article

References (27)

1. Hirsh J, Dalen E, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119: 8S-21S.
2. Furberg CD, Psaty BM, Manolio TA, et al. Prevalence of atrial fibrillation in elderly subjects (The Cardiovascular Health Study). Am J Cardiol 1994; 74: 238-241.
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991; 22: 983-988.
4. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of anti-thrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled studies. Arch Intern Med 1994; 154: 1449-1457.
5. Whitlon DS, Sadowski JA, Suttie JW. Mechanisms of coumadin action: significance of vitamin K epoxide reductase inhibition. Biochemistry 1978; 17: 1371-1377.
6. Hauschka PV, Lian JB, Cole DEC, et al. Osteocalcin and matrix Gla protein: vitamin K-dependent protein in bone. Physiol Rev 1989; 69: 990-1047.
7. Szulc P, Arlot M, Chapuy MC, Duboeuf F, Meunier PJ, Delmas P. Serum undercarboxylated osteocalcin correlates with hip bone mineral density in elderly women. J Bone Miner Res 1994; 9: 1591-1595.
8. Philip WJU, Martin JC, Richardson JM, Reid DM, Webster J, Douglas AS. Decreased axial and peripheral bone density in patients taking long-term warfarin. Q J Med 1995; 88: 635-640.
9. Piro LD, Whyte MP, Murphy WA, Birge SJ. Normal cortical bone mass after long term cournadin therapy. J Clin Endocrinol Metab 1982; 54: 470-473.
10. Sato Y, Honda Y, Kunoh H, Oizumi K. Long-term oral anticoagulation reduces bone mass in patients with previous hemispheric infarction and nonrheumatic atrial fibrillation. Stroke 1997; 28: 2390-2394.
11. Caraballo PJ, Gabriel SE, Castro MR, Atkinson EJ, Melton LJ. Changes in bone density after exposure to oral anticoagulants: a meta-analysis. Osteoporos Int 1999; 9: 441-448.
12. Caraballo PJ, Heit JA, Atkinson EJ, et al. Long-term use of oral anticoagulants and the risk of fracture. Arch Intern Med 1999; 159: 1750-1755.
13. Jamal SA, Browner WS, Bauer DC, Cummings SR. Warfarin use and risk for osteoporosis in elderly women. Ann Intern Med 1998; 128: 829-832.
14. Lukert BP, Raisz LR. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990; 112: 352-364.
15. Paul MD, Kerrigan J, Kelly AM, Braverman LE, Baran DT. Long-term L-thyroxin therapy associated with decreased hip bone density in premenopausal women. JAMA 1988; 259: 3137-3141.
16. Seeman E, Wahner HW, Offord KP, et al. Differential effects of endocrine dysfunction on the axial and appendicular skeleton. J Clin Invest 1982; 69: 1302-1309.
17. Goeree R, O'Brien B, Pettit D, et al. An assessment of the burden of illness due to osteoporosis in Canada. J Soc Obstet Gynecol Can 1996; 18: 15-24.
18. Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims databases in Quebec. J Clin Epidemiol 1995; 48: 999-1009.
19. Cooper C. Epidemiology and public health impact of osteoporosis. Baillieres Clin Rheumatol 1993; 7: 459-477.
20. Barbour LA, Kick SD, Steiner JF, et al. A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am J Obstet Gynecol 1994; 170: 862-869.
21. Thapa PB, Gideon P, Cost TW, Milam AB, Ray WA. Antidepressants and the risk of falls among nursing home residents. N Engl J Med 1998; 339: 875-882.
22. Ray WA, Griffin MR, Downey W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA 1989; 262: 3303-3307.
23. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. N Engl J Med 1995; 332: 767-773.
24. Grisso JA, Kelsey JL, Strom BL, et al. Risk factors for falls as a cause of hip fracture in women. N Engl J Med 1991; 324: 1326-1331.
25. Lacroix AZ, Wienpahl J, White LR, et al. Thiazide diuretic agents and the incidence of hip fracture. N Engl J Med 1990; 322: 286-290.
26. Cushenberry LM, de Bittner MR. Potential use of HMG-CoA reductase inhibitors for osteoporosis. Ann Pharmacother 2002; 36: 6716-6778.
27. Collet JP, Boivin JF, Spitzer WO. Bias and confounding in pharmacoepidemiology. In Pharmacoepidemiology (2nd edn), Strom BL (ed.). Churchill Livingstone: New York, 1994; 609-627.